KRT10 and neoplasm: Using B16-OVA, a melanoma tumor model expressing OVA, we evaluated these RNA-OG peptide complexes, containing ‘low’ (1 RNA-OG:13 pOVA-K10) or ‘high’ (1 RNA-OG:≥100 pOVA-K10) peptide amounts (see Table 1), for their induction of anti-tumor immunity.